Petlife Pharmaceuticals, Inc.
PTLF
$0.0001
$0.000.00%
| 02/28/2018 | 11/30/2017 | 08/31/2017 | 05/31/2017 | 02/28/2017 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -89.95% | -84.73% | 507.14% | 6,361.46% | 9,357.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -89.88% | -84.65% | 507.63% | 6,203.66% | 8,703.99% |
| Operating Income | 89.88% | 84.65% | -507.63% | -6,203.66% | -8,703.99% |
| Income Before Tax | 84.47% | 79.74% | -530.51% | -6,283.42% | -8,727.65% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 84.47% | 79.74% | -530.51% | -6,283.42% | -8,727.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 84.47% | 79.74% | -530.51% | -6,283.42% | -8,727.65% |
| EBIT | 89.88% | 84.65% | -507.63% | -6,203.66% | -8,703.99% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 96.92% | 94.99% | -150.44% | -2,694.44% | -4,173.90% |
| Normalized Basic EPS | 97.45% | 95.39% | -149.15% | -2,679.79% | -4,159.46% |
| EPS Diluted | 96.92% | 94.99% | -150.44% | -2,694.44% | -4,173.90% |
| Normalized Diluted EPS | 97.45% | 95.39% | -149.15% | -2,679.79% | -4,159.46% |
| Average Basic Shares Outstanding | 324.44% | 595.25% | 650.02% | 269.88% | 102.05% |
| Average Diluted Shares Outstanding | 324.44% | 595.25% | 650.02% | 269.88% | 102.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
